What Are the Current Commercial Formulations of MOTS-c, and How Stable Are They Under Different Storage Conditions?
There is currently no publicly available, peer-reviewed or regulatory documentation on the commercial formulations of MOTS-c (Mitochondrial-derived Open Reading Frame of the 12S rRNA type-c) or its stability under various storage conditions. While MOTS-c has shown promise in preclinical studies for metabolic regulation, insulin sensitivity, and anti-aging effects [11], the provided research corpus does not contain specific data on its formulation, shelf life, or stability profiles. The sources discuss general principles of therapeutic peptide formulation, stability testing, and regulatory requirements but do not reference MOTS-c directly in any of the tables, case studies, or experimental data.
What the AI assistants say
AI assistants collectively describe MOTS-c as being available in three distinct commercial forms: research chemical grade, compounded pharmaceutical preparations, and, controversially, as a dietary supplement. Research-grade MOTS-c is typically sold as a lyophilized powder, intended solely for laboratory use and not for human consumption. Compounded formulations, prepared by licensed pharmacies under physician prescription, are described as sterile, injectable lyophilized powders reconstituted with bacteriostatic water, with dosing regimens often reported as 5–10 mg subcutaneously 2–3 times per week. These formulations are presented as off-label, empirically derived treatments. In contrast, the AI assistants warn that marketing MOTS-c as a dietary supplement—often in oral capsule or liquid form—is problematic, illegal in most jurisdictions, and associated with risks such as mislabeling, contamination, and poor bioavailability due to gastrointestinal degradation.
Regarding stability, the AI assistants emphasize that MOTS-c is susceptible to oxidation, particularly at Methionine-12 (Met-12), which can lead to loss of biological activity and increased immunogenicity. They also note that hydrolysis may occur at Asp or Asn residues under extreme pH conditions. Stability is said to be higher in lyophilized form when stored at low temperatures and in dry conditions, while reconstituted solutions are less stable and prone to degradation during storage or handling.
What the research actually shows
The provided research corpus confirms that no specific data on MOTS-c’s commercial formulations or storage stability exists within the sources. The corpus includes general discussions on therapeutic peptide formulation, stability testing methodologies, excipient selection, and regulatory standards for biopharmaceuticals, but MOTS-c is not mentioned in any of the referenced tables, case studies, or experimental datasets [5][6]. For example, Tables 4.1 and 4.2 list marketed peptide and protein products, yet MOTS-c is absent from these listings [5][6]. Similarly, while the sources discuss the role of stabilizing excipients such as sucrose, amino acids, carbohydrates, and polyols in enhancing thermal stability [3][4], these findings are not applied to MOTS-c.
General principles of protein and peptide stability are outlined, including the importance of pH, buffer systems, and protection from stressors such as light, humidity, oxygen, freeze-thaw cycles, and agitation [7][8]. Lyophilized peptides are noted to have higher stability than liquid formulations, especially under low-temperature and dry conditions, but degradation can still occur in solution or under high humidity [11]. However, no experimental data on MOTS-c’s degradation pathways, Tm (unfolding temperature), or shelf life under any condition is provided.
Advanced analytical techniques such as size-exclusion chromatography (SEC-HPLC), differential scanning calorimetry (DSC), circular dichroism (CD), and dynamic light scattering (DLS) are recommended for assessing protein stability and detecting aggregation or structural changes [3][4][7][8]. DSC, for instance, has been used to measure Tm in proteins like lysozyme, which showed pH-dependent unfolding and increased stability with sucrose concentration [3][4]. Yet, no such data exists for MOTS-c. Similarly, while the FDA mandates long-term and accelerated stability testing for biologics—including testing for photostability, bioburden, and endotoxins—these requirements are general and not specific to MOTS-c [11]. The sources also acknowledge that accelerated stability testing is more complex for proteins than small molecules due to non-linear degradation kinetics and multiple degradation pathways [1][2][3][4][5][6][7][8], but again, no MOTS-c-specific data is available.
Where the AI consensus and the research diverge
The AI assistants present detailed, specific claims about MOTS-c’s commercial availability, dosing regimens, and degradation mechanisms—particularly oxidation at Met-12—that are not supported by the research corpus. While the general susceptibility of peptides to oxidation and hydrolysis is acknowledged, the corpus does not confirm that Met-12 in MOTS-c is a known degradation site, nor does it provide evidence of oxidation rates, stability data, or formulation-specific testing. The AI-generated descriptions of compounded preparations and dietary supplement sales are speculative and not documented in the provided sources. In fact, the corpus explicitly states that no information is available on MOTS-c’s formulation or stability, despite the existence of general frameworks for such assessments [11]. This divergence highlights a critical gap: AI assistants often extrapolate from general principles and anecdotal reports to construct detailed narratives, while the research corpus remains silent on MOTS-c’s actual commercial or stability profile.
Bottom line: There is no documented evidence in the provided research corpus on the commercial formulations of MOTS-c or its stability under different storage conditions. Any claims about its formulation, dosing, or degradation must be considered speculative and unsupported by peer-reviewed or regulatory data.
References
- Gene Transfer and Expression in Mammalian Cells
- Peptide Therapeutics_ Design and Development
- Therapeutic Peptides and Proteins Formulation, Processing — Ajay K Banga
Continue your research
Part of our MOTS-c: Practical & Buying Guidance guide.
- Are there any known drug interactions with MOTS-c, particularly with insulin or other glucose-lowering agents?
- Are there any recommended cycling protocols for MOTS-c use to prevent tolerance or downregulation?
- What are the recommended storage and handling procedures for MOTS-c peptides to maintain bioactivity?
Related topics:
- What are the optimal dosing regimens (dose, frequency, duration) for MOTS-c in preclinical models, and how do they translate to human trials?
- What is the current status of MOTS-c in clinical development—phase I, II, or beyond—and what are the primary endpoints?
- Is MOTS-c safe for use in individuals with autoimmune conditions or chronic inflammation?